Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay 31, 2018	Xencor to Present at Upcoming Investor Conferences MONROVIA, Calif. , May 31, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will	View HTML PDF Version
Toggle SummaryAug 05, 2014	Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference MONROVIA, Calif. , Aug. 5, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Desjarlais , Ph.D.,	View HTML Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference 12.8 KB
Toggle SummaryMay 15, 2020	Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II MONROVIA, Calif. --(BUSINESS WIRE)--May 15, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb ® 2+1	View HTML PDF Version
Toggle SummaryNov 04, 2020	Xencor to Present Data from Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 4, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that data from the ongoing Phase 1 dose-escalation study of	View HTML PDF Version
Toggle SummaryNov 04, 2021	Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 4, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that updated clinical data from its Phase 1	View HTML PDF Version
Toggle SummaryOct 01, 2021	Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 1, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster presentations at the 36th Annual	View HTML PDF Version
Toggle SummaryOct 14, 2020	Xencor to Present Data from the Phase 1 Study of XmAb®20717 and Three Research Programs at the SITC Annual Meeting MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 14, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced four poster presentations at the 35th Annual Meeting of the	View HTML PDF Version
Toggle SummaryOct 20, 2017	Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting -- Accepted for Late-Breaking Abstract Session --	View HTML Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting 90.8 KB
Toggle SummaryNov 01, 2018	Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting MONROVIA, Calif. , Nov. 1, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1	View HTML PDF Version
Toggle SummarySep 09, 2020	Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 9, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial data from its ongoing Phase 1 dose-escalation study	View HTML PDF Version

Tools

Press Releases